June 26, 2012

CHDP Provider Information Notice No.: 12-02

TO: ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP) PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE PLANS

SUBJECT: EXPANSION OF CHDP VACCINE BENEFIT FOR QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE (HPV4), CHDP CODE 76 TO ROUTINE USE IN MALES

The purpose of this Provider Information Notice (PIN) is to inform you that the gender criteria for quadrivalent Human Papillomavirus Vaccine (HPV4), CHDP code 76, has been changed from “routine for females with permissive use in males” to “routine use in females and males”.

In 2009, the Advisory Committee on Immunization Practices (ACIP) recommended the use of HPV4 for females to prevent cervical cancer. Stated recommendation in males was ‘permissive’ in order to prevent transmission to females and to prevent genital warts in females and males. In December 2011, the ACIP recommendation for HPV4 was expanded to routine use females and males. The recommended number and frequency for males is the same as for females, three doses of HPV4 beginning at age 11-12, and as early as age 9. The vaccine is recommended for males between ages 11 – 21. Although the ACIP recommendation is for the vaccine series to be given to males through age 21, at this time the vaccine is only payable through Vaccines For Children, which reimburses vaccines through age 18. Note: the Bivalent Human Papillomavirus Vaccine (HPV2) is for females only.

For more information about this vaccine recommendation, see the memo from the California Department of Public Health, Immunization Branch: www.eziz.org/assets/docs/vfcletter_2012_01_HPV4.pdf.
If you have administered HPV4 to a male between 9 and 19 years on or after October 21, 2009 and prior to this notice, you are entitled to reimbursement for the administration of this vaccine. Please submit a PM 160 for the $9.00 administration fee if you have not been previously reimbursed for the vaccine by any source.

Because there is no change to allowed vaccines, the CHDP Vaccine Benefit and Reimbursement Table is unchanged.

Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions about CHDP vaccine benefits or other CHDP issues, please contact your local CHDP program office.

Sincerely,

Robert Dimand M.D.
Chief Medical Officer
Children’s Medical Services